LCM
CHRS icon

Laurion Capital Management’s Coherus Oncology CHRS Stock Holding History

Laurion Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-147,646
Closed -$492K – 530
2023
Q4 		$492K Buy
147,646
+17,228
+13% +$46.1K ﹤0.01% 393
2023
Q3 		$488K Buy
+130,418
New +$602K ﹤0.01% 394
2018
Q3 		– Sell
-126,201
Closed -$1.77M – 1220
2018
Q2 		$1.77M Buy
126,201
+87,421
+225% +$1.25M 0.01% 631
2018
Q1 		$428K Buy
+38,780
New +$424K ﹤0.01% 1043

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Laurion Capital Management's CHRS Position: Q1 2024 in Review

Laurion Capital Management sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 147,646 shares — an estimated $492K sold.

Laurion Capital Management first reported a position in CHRS in Q1 2018 and held it in 4 quarters. The position peaked at $1.77M in Q2 2018. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

  • Laurion Capital Management reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
  • Laurion Capital Management sold 147,646 Coherus Oncology shares in Q1 2024, an estimated $492K.
  • Laurion Capital Management first reported a position in Coherus Oncology in Q1 2018 and held it in 4 quarters.
  • Laurion Capital Management's Coherus Oncology position peaked at $1.77M in Q2 2018.
  • 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Laurion Capital Management's 13F filing for Q1 2024, filed 15 May 2024.